Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11434393 | 0.81 | GABRA1 (0.39) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL2652817 | 0.79 | TDP2 (0.36) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL6060786 | 0.77 | POLB (0.32) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL2917414 | 0.77 | TRPA1 (0.32) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL15657373 | 0.77 | TRPA1 (0.32) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL18535707 | 0.77 | TRPA1 (0.37) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL2424548 | 0.77 | TRPA1 (0.37) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL10885410 | 0.77 | TRPA1 (0.48) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL10800866 | 0.74 | AR (0.33) | TRPA1ATMCYP1A2TSHRCYP2A6 | |
| SCHEMBL1360849 | 0.74 | TRPA1 (0.39) | TRPA1ATMCYP1A2TSHRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417143-B1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM AS (DK) | 2016-12-21 | — | — | EP | disclosed |
| US-9012625-B2 | Method for the synthesis of a trisaccharide | GLYCOM A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20130131334-A1 | METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | Glycom A/S Danmarks Tekniske Universitet (DK) | 2013-05-23 | — | — | US | disclosed |
| EP-2417143-A1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | Glycom A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115934-A1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
| EP-0009787-B2 | PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION | BAYER AG (DE) | 1986-07-09 | — | — | EP | disclosed |
| US-4331821-A | ULTRAVIOLET RADIATION OF A VAPORIZED ALKYLBENZEN AND HALOGEN GAS MIXTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0009787-B1 | PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION | BAYER AG (DE) | 1982-01-13 | — | — | EP | disclosed |
| EP-0009787-A2 | Process for the monohalogenation of alkylbenzenes in alpha position | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131334-A1 | METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | UGGT1, FUT6, MAN1B1 | TRPA1 4868/4885ATM 3447/4885CYP1A2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.